Premixed insulin analogues worth it in the long term in type 2 DM Meeting report 30 January 2013 Pages: 3 - 4
Hep A, B vaccine boosters not needed for majority of travellers Guideline 30 January 2013 Pages: 5 - 5
Insulin detemir + insulin aspart good value for DM in Germany Clinical study 30 January 2013 Pages: 7 - 7
Budesonide/formoterol good value for asthma maintenance in Europe Clinical study 30 January 2013 Pages: 8 - 8
Hospitalisation the major cost for pancreatic cancer in Germany Clinical study 30 January 2013 Pages: 8 - 8
Consider testing all therapy-naive patients for resistance in HIV Clinical study 30 January 2013 Pages: 9 - 9
Early and sustained clopidogrel therapy worth it in Europe Clinical study 30 January 2013 Pages: 9 - 9
New ideas needed to encourage daily folic acid use in the US Clinical study 30 January 2013 Pages: 9 - 9
Continuous SC insulin infusion worth it for diabetes in the UK Clinical study 30 January 2013 Pages: 10 - 10
Moxifloxacin tops in CAP regardless of resistance level Clinical study 30 January 2013 Pages: 10 - 10
Out-of-pocket spend substantial for patients with RA in Germany Clinical study 30 January 2013 Pages: 10 - 10
Eplerenone fits the bill for HF post-MI in France and Spain Clinical study 30 January 2013 Pages: 11 - 11
Finasteride not cost effective for prostate cancer prophylaxis Clinical study 30 January 2013 Pages: 11 - 11
Intensive education optimises antibacterial use, reduces resistance Clinical study 30 January 2013 Pages: 12 - 12
Orlistat + diet tackles obesity at reasonable cost in Sweden Clinical study 30 January 2013 Pages: 12 - 12
Bevacizumab drives ovarian cancer market, diagnostics market soars News item 30 January 2013 Pages: 14 - 14